The 23rd China International Pharmaceutical Ingredients Exhibition (CPHI China 2025) was held at the Shanghai New International Expo Center from June 24th to 26th. As a major event in the global pharmaceutical industry, this exhibition gathered nearly 3,500 exhibitors and over 100,000 professional visitors from around the world, becoming a key platform for upstream and downstream collaboration. Morning Shine Pharmaceutical presented its advanced capabilities in GLP-1 peptide drug intermediates, monodisperse PEG derivatives, and nucleic acid raw materials, drawing significant attention with its excellent product quality and technical advantages.

In November 2024, Morning Shine Pharmaceutical was re-designated as a "National High-Tech Enterprise." The official announcement can be found at the following link: Publicity on the Filing of the First Batch of High-Tech Enterprises Recognized and Submitted by Hunan's Certification Authority in 2024. This follows the company’s initial recognition in September 2021, which was valid for three years. This renewed recognition not only affirms the company’s strength in R&D and innovation but also underscores its growing role as a key provider of pharmaceutical technology and manufacturing solutions. Based in the Changsha High-Tech Zone, Morning Shine Pharmaceutical specializes in GLP-1 intermediates, fatty acid side chains, dipeptides, tetrapeptides, and high-purity monodisperse PEG derivatives—reinforcing its position within China’s national innovation ecosystem.1

On December 2, 2023, the Advanced Training Program on Key Technologies and Industrialization of Green High-Value Utilization of Natural Resources, co-hosted by the Human Resources and Social Security Department of Hunan Province, Hunan Normal University, and Changsha Morningstar Pharmaceutical Technology Co., Ltd., successfully concluded. The program attracted over 80 technical experts from provincial universities, research institutes, and enterprises, focusing on cutting-edge technology transfer in natural medicines and biopharmaceuticals, injecting innovative momentum into Hunan's "Three Highlands and Four New Missions" strategy.

On November 9, 2023, the Biotechnology Department of Changsha Morning Shine Co., Ltd. held a rich and colorful science popularization education class for the children of its employees. The course content included understanding cells, extracting DNA from bananas, observing onion cells and cancer cells under a microscope, culturing bacteria on their hands, and making delicious ice cream with liquid nitrogen. Let's take a look at how the children explored the world of science!

In October 2023, Hunan Morning Shine Co., Ltd. (hereinafter referred to as "Morning Shine ") announced the successful completion of a Series A financing of over 100 million RMB. This round of financing was led by YuanBio Venture Capital, with SUNZ FUND and Jinyu Maowu participating as follow-on investors. The funds raised will be used to strengthen the company's R&D and production capacity building, accelerate the development of new products, expand into overseas markets, and comprehensively accelerate the company's growth.